Suzetrigine Following Urogynecologic Surgery: Investigation of Postoperative Pain Management

Suzetrigine is a first-in-class, selective NaV1.8 inhibitor that provides peripheral analgesia without opioid-related CNS effects. It was approved by the FDA in 2025 as a non-opioid alternative for moderate-to-severe pain following Phase 3 studies in abdominoplasty and bunionectomy. This single-center, randomized, double-blinded, placebo-controlled trial evaluates whether a suzetrigine-based postoperative analgesic regimen reduces opioid consumption and improves pain control compared with standard opioid-inclusive care following apical suspension surgery for pelvic organ prolapse. The study will enroll participants in a 1:1 ratio and assess pain, opioid consumption, adverse events, and patient-reported recovery over 7 days postoperatively.